“I think the key [is to not] get rid of financial incentives. I don't think that's possible. [Rather, we should] align financial incentives [so] that [we] can promote what is best for patients,” says Lillian Y. Lai, MD.
In this video, Lillian Y. Lai, MD, discusses the findings of the Urology Practice study, “Commercial prices for prostatectomy and treatment among younger, privately insured men with prostate cancer.” Lai is a Society of Urologic Oncology fellow at the University of Michigan, Ann Arbor.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.